Membranes for the dehydration of solvents by pervaporation
PD Chapman, T Oliveira, AG Livingston, K Li - Journal of Membrane …, 2008 - Elsevier
This review aims at summarizing the main research carried out up to 2007 in hydrophilic
pervaporation. Both polymeric and inorganic membranes are examined and the dehydration of …
pervaporation. Both polymeric and inorganic membranes are examined and the dehydration of …
Assessing sediment contamination in estuaries
PM Chapman, F Wang - Environmental Toxicology and …, 2001 - Wiley Online Library
Historic and ongoing sediment contamination adversely affects estuaries, among the most
productive marine ecosystems in the world. However, all estuaries are not the same, and …
productive marine ecosystems in the world. However, all estuaries are not the same, and …
The science of hypoxia in the Northern Gulf of Mexico: a review
The Mississippi River is one of the world's 10 largest rivers, with average freshwater
discharge into the northern Gulf of Mexico (GOM) of 380km 3 year −1 . In the northern GOM, …
discharge into the northern Gulf of Mexico (GOM) of 380km 3 year −1 . In the northern GOM, …
[HTML][HTML] Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert… - … England Journal of …, 2011 - Mass Medical Soc
Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032)
have shown response rates of more than 50% in patients with metastatic melanoma with …
have shown response rates of more than 50% in patients with metastatic melanoma with …
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
…, B Mirakhur, ME Guckert, V Goodman, PB Chapman - The Lancet, 2012 - thelancet.com
Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable
safety profile in studies of phase 1 and 2 in patients with BRAF V600 -mutated metastatic …
safety profile in studies of phase 1 and 2 in patients with BRAF V600 -mutated metastatic …
[HTML][HTML] Inhibition of mutated, activated BRAF in metastatic melanoma
…, JF Grippo, K Nolop, PB Chapman - … England Journal of …, 2010 - Mass Medical Soc
Background The identification of somatic mutations in the gene encoding the serine–threonine
protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test …
protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test …
Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
K Hsiao, P Chapman, S Nilsen, C Eckman, Y Harigaya… - Science, 1996 - science.org
Transgenic mice overexpressing the 695-amino acid isoform of human Alzheimer β-amyloid
(Aβ) precursor protein containing a Lys 670 → Asn, Met 671 → Leu mutation had normal …
(Aβ) precursor protein containing a Lys 670 → Asn, Met 671 → Leu mutation had normal …
Comparison of photovoltaic array maximum power point tracking techniques
T Esram, PL Chapman - IEEE Transactions on energy …, 2007 - ieeexplore.ieee.org
The many different techniques for maximum power point tracking of photovoltaic (PV) arrays
are discussed. The techniques are taken from the literature dating back to the earliest …
are discussed. The techniques are taken from the literature dating back to the earliest …
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Tumor-derived exosomes are emerging mediators of tumorigenesis. We explored the function
of melanoma-derived exosomes in the formation of primary tumors and metastases in …
of melanoma-derived exosomes in the formation of primary tumors and metastases in …
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
B-RAF is the most frequently mutated protein kinase in human cancers 1 . The finding that
oncogenic mutations in BRAF are common in melanoma 2 , followed by the demonstration …
oncogenic mutations in BRAF are common in melanoma 2 , followed by the demonstration …